Company updateCNBC-TV18
Sai Life reiterates 15-20% growth targets as pharma firms diversify
Positive+16
GreyOak summary
Sai Life Sciences CFO Siva Chittor reiterated long-term targets of 15-20% annual revenue growth and 28-30% EBITDA margins. The company aims to capitalize on global pharma firms diversifying supply chains beyond China by offering integrated CRO and CDMO services. Sai Life is also expanding into peptides and clinical formulations to drive future growth.
What it affects
- Sai Life SciencesSAILIFEPositive +16
Reiterates 15-20% growth and 28-30% margin targets.Rolling sentiment Positive +64
Source
Read the original at CNBC-TV18More Sai Life Sciences news
- Sai Life Sciences shares surge 9% to record highBusiness Standard · Results ·
- Divis, Gland, Sai Life Sciences shares hit 52-week highsBusiness Today · Stock view ·
- Sai Life Sciences shares rally 9% after Q2 resultsEconomic Times · Results ·
- Sai Life shares hit record high on strong Q2 earningsBusiness Standard · Results ·
- Sai Life Sciences hits record high; Astral shares hit 52-wk lowCNBC-TV18 · Results ·